N8 Medical, LLC

Our goal is to provide coating technology to effectively prevent hospital-acquired infections from biofilm fouling of indwelling medical devices

Our CeraShield coated Biofilm-Resistant Endotracheal Tube, is specifically designed to combat Ventilator-Associated Pneumonia (VAP), the most common, deadly HAI in ICU. VAP adds over Ten Billion Dollars in annual global treatment costs.

FDA Has Designated CeraShield Endotracheal Tube (ETT) As A “Breakthrough Device”. Cerashield ETT Is Cleared For Routine Clinical Use In Brazil, Canada, Colombia And UAE.

View More

N8 Medical, LLC

Our goal is to provide coating technology to effectively prevent hospital-acquired infections from biofilm fouling of indwelling medical devices

Our CeraShield coated Biofilm-Resistant Endotracheal Tube, is specifically designed to combat Ventilator-Associated Pneumonia (VAP), the most common, deadly HAI in ICU. VAP adds over Ten Billion Dollars in annual global treatment costs.

FDA Has Designated CeraShield Endotracheal Tube (ETT) As A “Breakthrough Device”. Cerashield ETT Is Cleared For Routine Clinical Use In Brazil, Canada, Colombia And UAE.

Overview

N8 Medical, LLC, a clinical-stage medical device company, is at the forefront of commercializing innovative medical devices enhanced with a novel class of active compounds known as Ceragenins.

N8 Medical’s goal is to revolutionize the safety of indwelling medical devices and implants. By applying our innovative CeraShield coating to these devices, we aim to prevent Hospital-Acquired Infections (HAIs), thereby reducing the reliance on antibiotics and combating Antimicrobial Resistance (AMR).

  • The development of CeraShield, a specialized coating for medical devices, aimed at preventing infections.
  • Through our subsidiary, Kinnear Pharmaceuticals (www.kinnearpharma.com), we're advancing therapeutic research and drug development. Our focus is on creating treatments for a range of conditions, including cystic fibrosis (CF) and Kostmann’s disease, leveraging the unique properties of Ceragenins that mimic the activity of naturally occurring innate immune system compounds such as LL-37.
View More

Overview

N8 Medical, LLC, a clinical-stage medical device company, is at the forefront of commercializing innovative medical devices enhanced with a novel class of active compounds known as Ceragenins.

N8 Medical’s goal is to revolutionize the safety of indwelling medical devices and implants. By applying our innovative CeraShield coating to these devices, we aim to prevent Hospital-Acquired Infections (HAIs), thereby reducing the reliance on antibiotics and combating Antimicrobial Resistance (AMR).

As an integral part of N8 Biosciences, a holding company committed to the extensive application of Ceragenins, N8 Biosciences is making strides in two key areas :

  • The development of CeraShield, a specialized coating for medical devices, aimed at preventing infections.
  • Through our subsidiary, Kinnear Pharmaceuticals (www.kinnearpharma.com), we're advancing therapeutic research and drug development. Our focus is on creating treatments for a range of conditions, including cystic fibrosis (CF) and Kostmann’s disease, leveraging the unique properties of Ceragenins that mimic the activity of naturally occurring innate immune system compounds such as LL-37.
View More

Science

Ceragenins A Synthesis of Nature and Innovation

Pipeline

Our lead medical device is our CeraShield Endotracheal Tube which FDA has designated as a “breakthrough device” and is approved for routine clinical use in Canada, Colombia, Brazil and other ex US countries. We expect FDA approval in 2024. The CeraShield ETT is designed to prevent Ventilator Associated Pneumonia (VAP) which is most common, deadly and costly HAI among ICU patients. The estimated worldwide costs associated with treating VAP exceeds Ten Billion Dollars annually.

Device

Designation

Indication

Research

Pre-clinical

Clinical

Commercialization

Partnership

Biofilm-preventing
Endotracheal tube

Medical device, indwelling

Prevention of VAP / VARI

Antimicrobial absorbable Pacemaker envelope

Medical device, implant

Prevention of CIED infections

JDA in discussion

Coated pedicle screw

Medical device, implant

Prevention of implant-associated orthopedic infections

JDA in discussion

View More

Leadership

News

N8 Medical and USAMRIID Enter CRADA to Test CSA Compounds Against Anthrax and other Biodefense Pathogens

•
August 25, 2023
•
Uncategorized

N8Medical has entered into a CRADA with USAMRIID in support of Core Antibiotic Screening Program. Will test CSAs against biodefense

View More »

FDA grants QIDP Designation For Kinnear’s CSA-131 drug for Life-threatening Pseudomonas Bacterial Infections in CF

•
August 25, 2023
•
Uncategorized

FDA QiDP designation is a significant milestone PARK CITY, UTAH, UNITED STATES, July 31, 2023/EINPresswire.com/ — Kinnear Pharmaceuticals, LLC, a

View More »

NIH Awards N8 Medical Two Additional SBIR Grants to Develop CeraShieldTM Coated Hemodialysis Catheters and Pedicle Screws

•
January 6, 2023
•
N8 Medical News

View More »

N8 Medical Is Awarded Almost $2 Million in Phase II SBIR Grant

•
July 5, 2022
•
N8 Medical News

View More »

Contact us

Contact us

Lets Get in Touch!

  • info@n8medical.com
  • N8 Medical LLC - 545 Metro Place, Dublin, OH, 43107
Follow now
Linkedin

mynewform

Basic contact form

N8 Medical, Inc. (N8 Medical) is a clinical-stage medical device company focused on commercializing medical devices that incorporate a novel class of active compounds called ceragenins.The subsidiaries for N8 Medical Inc are N8 Medical, LLC for Medical Device Development and Kinnear Pharmaceuticals, LLC for drug development.

Useful Links

Our Company